Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
39.66
-0.27 (-0.68%)
At close: Jun 20, 2025, 4:00 PM
39.70
+0.04 (0.10%)
After-hours: Jun 20, 2025, 6:08 PM EDT
Revolution Medicines Stock Forecast
Stock Price Forecast
The 12 analysts that cover Revolution Medicines stock have a consensus rating of "Strong Buy" and an average price target of $68.67, which forecasts a 73.15% increase in the stock price over the next year. The lowest target is $55 and the highest is $82.
Price Target: $68.67 (+73.15%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 14, 2025.
Analyst Ratings
The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 7 | 7 | 7 |
| Buy | 6 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $73 → $72 | Strong Buy | Maintains | $73 → $72 | +81.54% | May 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $70 → $75 | Buy | Maintains | $70 → $75 | +89.11% | May 8, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $87 → $80 | Strong Buy | Maintains | $87 → $80 | +101.71% | May 8, 2025 |
| Needham | Needham | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +43.72% | May 8, 2025 |
| Wedbush | Wedbush | Buy Reiterates $67 | Buy | Reiterates | $67 | +68.94% | Apr 28, 2025 |
Financial Forecast
Revenue This Year
1.38M
Revenue Next Year
4.70M
from 1.38M
Increased by 241.39%
EPS This Year
-4.81
from -3.58
EPS Next Year
-5.18
from -4.81
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.2M | 43.6M | 570.7M | ||
| Avg | 1.4M | 4.7M | 140.0M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 3,063.0% | 12,039.5% | ||
| Avg | - | 241.4% | 2,877.7% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.86 | -4.29 | -1.70 | ||
| Avg | -4.81 | -5.18 | -4.84 | ||
| Low | -4.71 | -5.48 | -5.80 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.